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Third, socioeconomic status is a stronger pre-
dictor of obesity among normal-weight children 
than among overweight children. The relative risk 
of becoming obese among children with lower 
socioeconomic status as compared with children 
with higher socioeconomic status was greater 
for normal-weight kindergartners than for over-
weight kindergartners.
The patterns of the incidence of obesity dur-
ing childhood indicate the complexities of the 
socioeconomic context of this health problem 
and the reach of the risk of obesity across the 
socioeconomic spectrum in the United States.
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A Trial of Mass Isoniazid Preventive Therapy  
for Tuberculosis Control
To the Editor: In reporting the results of the 
Thibela TB study, Churchyard and colleagues 
(Jan. 23 issue)1 suggest that continuous isoniazid 
preventive therapy should be considered for per-
sons at highest risk for tuberculosis (e.g., people 
with human immunodeficiency virus [HIV] infec-
tion), even though several studies in sub-Saharan 
Africa (including theirs) have shown that the 
protective effect of isoniazid preventive therapy 
has limited durability among HIV-infected adults. 
What their study implies, instead, is a need to 
discourage the use of isoniazid preventive ther-
apy in areas where there is a high incidence of 
transmission of tuberculosis and HIV infection 
and to urgently reassess the data regarding the 
use of isoniazid preventive therapy in these areas, 
since isoniazid preventive therapy is increasingly 
recommended in regions of Africa where there is 
a high burden of tuberculosis and HIV infection.2
In high-incidence areas, 4% of asymptomatic 
patients who have HIV infection and smear-
negative tuberculosis with normal findings on 
chest radiography have positive sputum cultures 
for Mycobacterium tuberculosis,3 and up to 30% of 
persons with HIV-associated tuberculosis discon-
tinue treatment for tuberculosis, in part because 
of gaps in the health systems in low-income and 
middle-income countries.4,5 Therefore, continu-
ous isoniazid preventive therapy in areas with a 
high prevalence of tuberculosis and HIV infection 
may cause drug pressure, the spread of drug-
resistant tuberculosis, or both, especially since 
there are limited methods of diagnosis and 
treatment for people who have latent infection 
with drug-resistant strains of M. tuberculosis.
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To the Editor: We question the reported benefit 
of isoniazid in the post hoc analysis in the Thi-
bela TB study, since patients with tuberculosis 
who were receiving treatment for tuberculosis or 
isoniazid preventive therapy at the time of the 
baseline survey were excluded from the interven-
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tion group. A lack of screening in the “control” 
group may fully explain the short-term differ-
ences in the incidence of tuberculosis between 
the two groups.
In the corresponding editorial, Rubin1 draws 
the conclusion that persons who are involved in 
the prevention of tuberculosis need to improve 
case detection, treatment, and adherence, as well 
as implement other “technical improvements.” It 
seems that — in an era of effective treatment 
— those of us in the field have become blind to 
the prevention benefits of nonmedical interven-
tions (e.g., improvements in ventilation2). There 
is a growing consensus that biomedical solu-
tions will be insufficient to tackle the tuberculo-
sis epidemic in low-income and middle-income 
countries.3 Given other negative trials of isonia-
zid preventive therapy 4 and enhanced case find-
ing,5 a renewed focus on environmental inter-
ventions is called for. Or, more controversially, 
perhaps nontargeted isoniazid preventive ther-
apy should be shelved altogether.
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The Authors Reply: We agree with Ukwaja and 
Abimbola that screening to identify people with 
active tuberculosis and link them to effective 
treatment is an important part of any isoniazid 
preventive therapy intervention. We also agree 
that drug resistance is amplified by weak tuber-
culosis treatment programs. Studies have not 
shown that isoniazid preventive therapy promotes 
isoniazid resistance.1 The prevention of tuber-
culosis, including drug-resistant tuberculosis, re-
quires a comprehensive strategy, of which isoni-
azid preventive therapy is a key component.
Richardson and Wood suggest that the direct 
effect of isoniazid preventive therapy in our trial 
was due to screening. We think this is unlikely. 
In our analysis of the direct effect of isoniazid, 
there was a dose–response effect: increasing pro-
tection against active tuberculosis with the in-
creasing number of months in which isoniazid was 
dispensed (see Table S4 in the Supplementary 
Appendix, available with the full text of our arti-
cle at NEJM.org). Furthermore, to minimize any 
screening effect, we excluded patients with tuber-
culosis who were identified in the first 3 months 
of follow-up (in both groups), and the protective 
effect of isoniazid was 49% as compared with 
the control cohort (Section S10 in the Supple-
mentary Appendix). Thus, we think that isonia-
zid preventive therapy has a protective effect that 
is not attributable to screening alone.
We agree that a “combination prevention” ap-
proach is required to improve tuberculosis con-
trol, including earlier diagnosis of infectious 
tuberculosis and a reduction in the number of 
patients who are initially lost to follow-up. Infec-
tion control in health facilities, which includes 
intensified case finding and administrative mea-
sures in addition to improved ventilation, is an 
important and neglected component of tubercu-
losis prevention. Improved ventilation alone, how-
ever, will not address the problem of reactivation 
of tuberculosis among the millions of people 
who have latent tuberculosis infection, particu-
larly those at highest risk, such as persons who 
are HIV-positive. In areas where it is feasible, 
tuberculin skin testing can identify people at 
highest risk for reactivation of tuberculosis who 
are most likely to benefit from preventive ther-
apy.2 In areas in which this testing is not feasi-
ble, the lack of a tuberculin skin test result should 
not be an obstacle to delivering an effective inter-
vention.3 Continuous isoniazid preventive therapy 
provides more protection than a 6-month course 
of isoniazid therapy in patients at highest risk.4
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Helicase–Primase Inhibitor Pritelivir for HSV-2 Infection
To the Editor: In the context of growing herpes 
simplex virus (HSV) resistance to licensed antivi-
ral agents targeting HSV DNA polymerase,1 espe-
cially HSV resistance to acyclovir in immuno-
compromised patients, the results reported by 
Wald and colleagues (Jan. 16 issue)2 spark great 
interest. In this trial, the specific helicase–pri-
mase inhibitor pritelivir exhibited activity for the 
treatment of HSV-2 genital infection. To date, 
four mutations leading to reduced HSV-2 suscep-
tibility to pritelivir have been identified within 
the UL5 gene, encoding HSV-2 helicase.3 We per-
formed a sequence analysis of the full-length UL5 
gene from 36 acyclovir-sensitive and 6 acyclovir-
resistant HSV-2 clinical isolates previously de-
scribed.4 Our results showed a weak variability of 
HSV-2 helicase, with an interstrain identity of 
more than 99.7% at both the nucleotide and ami-
no acid levels and no significant difference ac-
cording to the acyclovir-resistance profile. No 
preexisting mutation conferring resistance to 
pritelivir was detected, including in the acyclovir-
resistant HSV-2 isolates. These data provide some 
information on the polymorphisms of HSV-2 he-
licase (Fig. 1). Extended genotypic characteriza-
tion of the HSV helicase–primase complex is re-
quired to facilitate the identification of potential 
mutations of HSV that may confer resistance to 
helicase–primase inhibitors.
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Figure 1. Genetic Variability of HSV-2 Helicase.
Sequencing of HSV-2 helicase (881 amino acids) revealed a series of six conserved regions and functional domains 
(I through VI), indicated by the gray boxes. Amino acid changes related to natural polymorphisms are indicated by 
vertical bars. Underlined mutations are known to be involved in the acquisition of reduced susceptibility to pritelivir. 
Numbers denote amino acid positions.
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